Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Four antipsychotics and social cognition/metabolic effects in stable schizophrenia
ChiCTR1800016707Phase 4Recruiting
- Sponsor
- Mental Health Center of Xuhui District Shanghai
- Start
- Jan 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clozapine, Aminazin, risperidone and olanzapine in schizophrenia (5 arms), sponsored by Mental Health Center of Xuhui District Shanghai. Primary endpoints: MATRICS Consensus Cognitive Battery, Positive and Negative Syndrome Scale and 3 more. Started Jan 2017; status: recruiting.
02
Drugs
clozapineAminazinrisperidoneolanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR1800016707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016707.